NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing Clinical Development
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals has dosed the first patient in the MAD Part 2 of its Phase 1 trial for DA-1726, an obesity treatment. Top-line data for Part 1 is expected in Q3 2024, and for Part 2 in Q1 2025. A planned Part 3 will assess weight loss at 24 weeks. The company has secured $70M in financing to fund ongoing clinical development.
June 26, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroBo Pharmaceuticals has initiated the MAD Part 2 of its Phase 1 trial for DA-1726, targeting obesity treatment. The company expects top-line data in Q3 2024 and Q1 2025, and has secured $70M in financing to support ongoing clinical development.
The initiation of the MAD Part 2 trial and the secured $70M financing are positive developments for NeuroBo Pharmaceuticals. These steps indicate progress in their clinical trials and financial stability, which are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100